Granite Group Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-4,674
Closed -$325K 80
2025
Q1
$325K Hold
4,674
0.23% 50
2024
Q4
$402K Sell
4,674
-14
-0.3% -$1.51K 0.26% 38
2024
Q3
$558K Hold
4,688
0.36% 31
2024
Q2
$669K Hold
4,688
0.51% 32
2024
Q1
$602K Hold
4,688
0.41% 39
2023
Q4
$615K Buy
+4,688
New +$464K 0.44% 38

Other funds holding NVO

Granite Group Advisors's NVO Position: Q2 2025 in Review

Granite Group Advisors sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 4,674 shares — an estimated $325K sold.

Granite Group Advisors first reported a position in NVO in Q4 2023 and held it in 6 quarters. The position peaked at $669K in Q2 2024. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Granite Group Advisors reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Granite Group Advisors sold 4,674 Novo Nordisk shares in Q2 2025, an estimated $325K.
  • Granite Group Advisors first reported a position in Novo Nordisk in Q4 2023 and held it in 6 quarters.
  • Granite Group Advisors's Novo Nordisk position peaked at $669K in Q2 2024.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Granite Group Advisors's 13F filing for Q2 2025, filed 28 Jul 2025.